The oral transmucosal drugs market size is expected to see strong growth in the next few years. It will grow to $56.83 billion in 2028 at a compound annual growth rate (CAGR) of 9.4%. The growth in the forecast period can be attributed to advancements in personalized medicine, increasing research on novel drug delivery systems, expanding geriatric population, growing awareness of oral health, rising demand for non-invasive treatments, and evolving regulatory landscapes. Major trends in the forecast period include adoption of novel formulations, personalized medicine approaches, telehealth advancements, integration of digital health technologies and technological innovations in pharmaceuticals.
Order your report now for swift delivery, visit the link:
https://www.thebusinessresearchcompany.com/report/oral-transmucosal-drugs-global-market-report
Segmentation & Regional Insights
The oral transmucosal drugs market covered in this report is segmented –
1) By Product Type: Tablets, Films, Liquid And Spray, Other Product Types
2) By Indication: Opioid Dependence, Nausea And Vomiting, Erectile Dysfunction, Neurological Disorders, Other Indications
3) By Route Of Administration: Sublingual Mucosa, Buccal Mucosa, Other Routes Of Administration
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
North America was the largest region in the oral transmucosal drugs market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oral transmucosal drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15627&type=smp
Major Driver Impacting Market Growth
The rising incidence of Parkinson’s disease is expected to propel the growth of the oral transmucosal drug market going forward. Parkinson’s disease refers to a progressive neurological condition causing tremors, stiffness, and movement difficulties due to a reduction in dopamine-producing cells in the brain. The rising prevalence of Parkinson’s disease is due to aging demographics, environmental pollutants, genetic susceptibilities, and advancements in diagnostic capabilities that enhance detection rates. Oral transmucosal drugs support Parkinson’s disease treatment by facilitating fast drug absorption and overcoming digestive challenges, leading to faster relief, better adherence, and possibly fewer motor complications. For instance, in December 2022, according to the Parkinson’s Foundation, a US-based non-profit organization, approximately 1 million individuals in the United States currently have Parkinson’s disease (PD), which is expected to increase to 1.2 million by 2030. Therefore, the rising incidence of Parkinson’s disease is driving the growth of the oral transmucosal drug market.
Key Industry Players
Major companies operating in the oral transmucosal drugs market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Sanofi-Aventis LLC, AstraZeneca PLC, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Eli Lilly & Company Ltd., Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceutical Industries Ltd., Biogen Inc., Actavis Pharma Inc., Sun Pharmaceutical Industries Limited, Dr. Reddy’s Laboratories Ltd., Endo Pharmaceuticals Inc., Lupin Limited, Zydus Lifesciences Limited, Mallinckrodt Pharmaceuticals Plc, Glenmark Pharmaceuticals Limited, Jubilant Life Sciences Limited, Torrent Pharmaceuticals Ltd., Alembic Pharmaceuticals Ltd, Wockhardt Ltd.
The oral transmucosal drugs market report table of contents includes:
1. Executive Summary
2. Oral Transmucosal Drugs Market Characteristics
3. Oral Transmucosal Drugs Market Trends And Strategies
4. Oral Transmucosal Drugs Market – Macro Economic Scenario
5. Global Oral Transmucosal Drugs Market Size and Growth
………………………………….
32. Global Oral Transmucosal Drugs Market Competitive Benchmarking
33. Global Oral Transmucosal Drugs Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Oral Transmucosal Drugs Market
35. Oral Transmucosal Drugs Market Future Outlook and Potential Analysis
36. Appendix
Explore the trending research reports from TBRC:
https://goodprnews.com/cancer-immunotherapy-drug-discovery-outsourcing-global-market-size/
https://goodprnews.com/complementary-and-alternative-medicine-global-market-size/
https://goodprnews.com/ecotoxicological-studies-global-market-size/
https://topprnews.com/cancer-immunotherapy-drug-discovery-outsourcing-global-market-share/
https://topprnews.com/complementary-and-alternative-medicine-global-market-share/
https://topprnews.com/ecotoxicological-studies-global-market-share/
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
